Trial Profile
Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Nov 2016 New trial record
- 10 Nov 2016 Status changed from not yet recruiting to recruiting.